

This is a Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Company's performance. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

19 April 2021



Directa Plus plc
("Directa Plus" or the "Company")

New G+ Coating for Fabrics Dermatologically Tested

Human patch test results establish coating as suitable for skin contact

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, announces that the Company's new G+[®] graphene coating for fabrics has been tested by an independent third party laboratory and found to be suitable for human skin contact. Since 2014, Directa Plus has commissioned 28 tests on different morphologies of G+[®] graphene, all of which have certified the absence of any negative impacts on biological systems.

The latest test was a human patch test, using volunteers, to assess any potential side effects (skin erythema and oedema reactions) that may occur after applying the G+[®] product and to evaluate whether the product is safe for consumer use. The results showed zero erythema and oedema reactions across all subjects participating in the test and the G+[®] coated fabric was reported to be 'dermatologically tested' and non-irritating.

The G+[®] coating has been developed specifically for the automotive, upholstery, interior design, accessories and consumer electronics markets. It is thermally and electrically conductive, antibacterial and antiviral (certified to be anti-sars cov-2), UV and abrasion-resistant and can be applied to a wide variety of substrates, from natural and artificial fabrics to non-woven and microfiber, as well as felt and leather.

Giulio Cesareo, Chief Executive of Directa Plus, commented: "As always, our products are tested to the highest possible standards before releasing them to our target markets. Because our products are dermatologically tested to be non-toxic and hypoallergenic, Directa's business partners can develop innovative new products knowing that they will be safe for their own consumers."

For further information please visit <http://www.directa-plus.com/> or contact:

Directa Plus plc	+39 02 36714458
Giulio Cesareo, CEO	
Cenkos Securities plc (Nominated Adviser and Joint Broker)	+44 131 220 6939
Neil McDonald / Pete Lynch	
N+1 Singer (Joint Broker)	+44 20 7496 3069
Rick Thompson / Phil Davies	

Tavistock (Financial PR and IR)

Simon Hudson / Edward Lee

+44 20 7920 3150

About Directa Plus

Our focus is principally on the two sectors in which we have strong commercial advantage through developed and launched products and a technological lead: environmental (based on our Grafysorber® product), textiles (based on our G+ products) and more recently, lithium-sulphur batteries. In addition, we will continue to pursue opportunities in elastomers and composites (including tyres and asphalt), also using our G+ products. All our products are hypoallergenic, non-toxic and sustainably produced.

-ends-